David Reese, Amgen
As tezepelumab awaits FDA decision, Amgen and AstraZeneca tout more data from the Phase III study
As AstraZeneca and Amgen’s Dupixent challenger awaits a decision by the FDA, the companies are touting new data they hope could bolster their case. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
